Asset
NOMLABOFUSP
LARIMAR THERAPEUTICS INC. COMMON STOCK
Revenue
No revenue reported in loaded filings.
Clinical trials (6)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT05579691 | phase2 | completed | 2022-09-21 | 2023-12-04 | Larimar Therapeutics, Inc. | A Double-Blind, Placebo-Controlled, Dose Exploration Study of CTI-1601 in Adult Subjects With Friedreich's Ataxia |
| NCT06681766 | phase1 | terminated | 2024-12-06 | 2025-04-27 | Larimar Therapeutics, Inc. | A Study to Assess Nomlabofusp in Adolescents and Children With Friedreich's Ataxia |
| NCT07778836 | phase3 | recruiting | 2026-10-26 | 2029-07-01 | Larimar Therapeutics, Inc. | A Study to Evaluate the Efficacy and Safety of Subcutaneous Nomlabofusp in Subjects With Friedreich's Ataxia |
| NCT06447025 | phase2 | recruiting | 2024-01-25 | 2027-01-01 | Larimar Therapeutics, Inc. | An Open-Label Study of CTI-1601 in Subjects With Friedreich's Ataxia |
| NCT04519567 | phase1 | completed | 2020-07-31 | 2021-03-16 | Larimar Therapeutics, Inc. | Multiple Ascending Dose Study of CTI-1601 Versus Placebo in Subjects With Friedreich's Ataxia |
FDA applications (0)
This company has no applications containing this asset.